MarginsXMarginsX
Home › Markets › Health Care › LQDA

Liquidia Corporation (LQDA)

LQDA trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$56.37
-1.81% on the day
Market cap
$5.1B
Mid cap
Revenue · 2025
$158.3M
+1031.2% on 2024
Net income · 2025
-$68.9M
-43.5% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1819576/000110465926023804/0001104659-26-023804-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerLQDA on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2018
SEC CIK0001819576
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials · 2025

LineValue
Revenue$158.3M
Net income-$68.9M
Operating income-$51.4M
Net margin-43.5%
Operating margin-32.5%
Revenue growth+1031.2%
Cash$190.7M
Total assets$327.9M
P/E (computed)Net income was not positive
P/S (computed)32.1×

Warning signs

Cash runway
Cash-flow positive
$396.1M cash at September 30, 2026
Share count, 1 year
+3.6%
2025-10-20 to 2026-10-28 · +38.8% over 3 years
Going-concern doubt
No
10-Q filed November 10, 2026
Insider net buying, 12 months
-$222.3M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-10
Cash and burn$396.1M cash; operating cash flow $81.0M a quarter.Report 2026-09-30
Shares outstanding90,106,442 (2026-10-28); 86,995,483 a year earlier; 64,905,495 three years earlier.Cover page 2026-10-28
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months1 S-3/F-3 shelf filings; 0 424B5 takedownsLatest 2026-03-05
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorPricewaterhouseCoopers LLP, Raleigh, North Carolina, United StatesPCAOB Form AP 2026-03-20
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $318K, sold $222.6M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$225.3M-$236.3M$146.7M$396.1MNo debt tags$621.9M10-Q 2026-11-10
Q2 2026
2026-06-30
$171.7M$74.7M$80.2M$284.2MNo debt tags$450.9M10-Q 2026-08-12
Q1 2026
2026-03-31
$132.9M$52.9M$53.0M$222.8MNo debt tags$288.1M10-Q 2026-05-11
Q4 2025
2025-12-31
$92.0M$14.6M$44.2M$190.7MNo debt tags$158.3M10-K 2026-03-05
Q3 2025
2025-09-30
$54.3M-$3.5M-$9.8M$157.5MNo debt tags$69.2M10-Q 2026-11-10
Q2 2025
2025-06-30
$8.8M-$41.6M-$39.5M$173.4MNo debt tags$19.3M10-Q 2026-08-12
Q1 2025
2025-03-31
$3.1M-$38.4M-$30.7M$169.8MNo debt tags$14.1M10-Q 2026-05-11
Q4 2024
2024-12-31
$2.9M-$38.5M-$20.8M$176.5MNo debt tags$14.0M10-K 2026-03-05

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering documentS-3ASR2026-03-05
Latest annual report10-K2026-03-05
Latest quarterly / interim10-Q2026-11-10
Latest current report
FORM 8-K
8-K2026-11-10
Latest proxyDEFA14A2026-04-24

Source: SEC EDGAR submissions feed, 704 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+29.3%
1 month+114.1%
3 months-20.4%
Year to date+66.5%
1 year+113.1%
From 52-week high-36.9%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
PTCTPTC Therapeutics Inc.$60.97-3.97%$5.1B
DNTHDianthus Therapeutics Inc.$89.55-2.46%$5.0B
ERASErasca Inc.$15.11-3.51%$5.3B
EWTXEdgewise Therapeutics Inc.$43.68-4.90%$4.8B
MANEVeradermics Incorporated$128.05-1.24%$5.4B
COGTCogent Biosciences Inc.$27.44-3.92%$4.8B
TVTXTravere Therapeutics Inc.$49.70-1.88%$4.8B
IONSIonis Pharmaceuticals Inc.$28.01-3.61%$4.7B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier